17
total announcements
JENBURPH.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 05 Nov 2026
Market Cap
₹410 Cr
P/E (TTM)
12.5
P/E (Forward)
26.7
EPS (TTM)
₹74.39
52W Low
₹848.05
52W High
₹1,317.00
Dividend Yield
2.30%
Beta
0.40
Price / Book
2.1
Debt / Equity
1.3
Revenue (TTM)
₹169 Cr
Gross Margin
80.09%
Operating Margin
15.17%
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Counter Cyclical Investment Pvt Ltd.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has published its unaudited standalone financial results for the quarter and half year ended on 30th September, 2026, in accordance with Regulation 33 read with Regulation 47(1) of the SEBI Listing Obligation & Disclosure Requirements Regulations, 2015.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter and half year ended on 30 September, 2026, with a net profit of ₹1020.94 crore and earnings per share of ₹23.13.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter and half year ended on 30th September, 2026, with a profit after tax of ₹1020.94 crore and earnings per share of ₹23.13.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has scheduled a Board Meeting on 03/11/2026 to consider and approve standalone unaudited financial results for the quarter and half year ended on 30/09/2026.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Counter Cyclical Investment Pvt Ltd.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has submitted a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September, 2026, indicating that securities received for dematerialization have been processed and listed on the stock exchange.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has been admitted to dealings on the Capital Market Segment of NSE under the 'Permitted to Trade' category, effective from 17th August, 2026, without the company's explicit listing application. The company's equity shares continue to be listed on BSE Limited.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced the closure of its trading window from 1st October, 2026, until 48 hours after the dissemination of its unaudited financial results for the quarter and half year ending on 30th September, 2026.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced the elevation of Shri. Prem Ashish Bhuta to Associate Vice President (AVP) – Strategic Initiatives, a senior management position, effective September 4, 2026. The appointment was made by the Board of Directors through a resolution passed by circulation.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has published its standalone unaudited financial results for the quarter ended on 30th June, 2026. The results are available on the company's website and the BSE website.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter ended on 30th June, 2026, with a profit before tax of Rs. 676.91 crores and a net profit of Rs. 588.56 crores.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter ended 30 June 2026, with revenue from operations at Rs 3551.20 crore and profit after tax at Rs 588.56 crore.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 4, 2026, through video conferencing. The notice, along with the annual report for the financial year 2025-26, has been sent to members through electronic mode. Members will be able to cast their votes using the electronic voting system provided by National Securities Depository Limited (NSDL) from September 1 to 3, 2026.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 4, 2026, through video conferencing. The meeting will consider various resolutions, including the adoption of audited financial statements, dividend declaration, and reappointment of the Whole Time Director and CFO.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has submitted its Annual Report for FY 2025-26, including audited standalone financial statements, auditors' report, and directors' report. The report also includes a notice convening the 41st Annual General Meeting to be held on September 4, 2026, and proposes to declare a dividend of ₹ 20.70 per equity share.
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd has scheduled a Board Meeting on 06/08/2026 to consider and approve standalone unaudited financial results for the quarter ended 30/06/2026.